A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis

INTRODUCTION: Interstitial pneumonia (IP) is one of the most common and poor prognostic comorbidities in patients with NSCLC and a known risk factor for pneumonitis. Atezolizumab monotherapy is an established treatment for recurrent NSCLC and reported to have a lower risk of pneumonitis than program...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Ikeda, Satoshi, Kato, Terufumi, Kenmotsu, Hirotsugu, Ogura, Takashi, Iwasawa, Shunichiro, Sato, Yuki, Harada, Toshiyuki, Kubota, Kaoru, Tokito, Takaaki, Okamoto, Isamu, Furuya, Naoki, Yokoyama, Toshihide, Hosokawa, Shinobu, Iwasawa, Tae, Yamanaka, Takeharu, Okamoto, Hiroaki
Formato: Artigo
Idioma:Inglês
Publicado em: International Association for the Study of Lung Cancer. Published by Elsevier Inc. 2020
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446731/
https://ncbi.nlm.nih.gov/pubmed/32858235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2020.08.018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados